Showing posts with label coenzyme Q-10. Show all posts
Showing posts with label coenzyme Q-10. Show all posts

Thursday, October 30, 2014

Another major supplement, creatine, proven ineffective in the fight against Huntington’s disease

For the second time in less than three months, a widely taken and long-studied dietary supplement envisioned as a potential treatment for Huntington’s disease has been proven ineffective, bringing a halt to a clinical trial.

Creatine, a supplement popular among body builders and readily available in health food stores, was studied in a clinical trial called CREST-E (Creatine Safety, Tolerability, and Efficacy in Huntington’s Disease), which began in 2009 and was to be completed in 2016.

On October 29, the National Center for Complementary and Alternative Medicine, part of the National Institutes of Health (NIH), announced that it was discontinuing CREST-E because a preliminary analysis of the data “showed with high confidence that it was unlikely that the study would be able to show that creatine was effective in slowing loss of function in early symptomatic Huntington’s Disease.”

The study was carried out by the Huntington Study Group (HSG) and led by Dr. Steven Hersch of Massachusetts General Hospital and Dr. Giovanni Schifitto of the University of Rochester School of Medicine.

“The entire point of the CREST-E study was to determine whether creatine slows the course of HD or not, and the answer is, no, it does not,” Martha Nance, M.D., a member of the HSG executive committee, said in an e-mail. “Although this result is disappointing, it is still important, as it gives us a definite answer to the question: ‘I have HD. Should I take creatine?’ The answer is, ‘no.’”

“I recommend that all stop taking creatine,” Dr. LaVonne Goodman, the founder of Huntington’s Disease Drug Works (HDDW), said in an e-mail.

False hopes

Huntington’s disease typically reduces people’s energy levels. Scientists thought that creatine, which cells use to store energy, might help compensate for the energy deficit in brain cells and enable them to survive.

Positive results in animal studies regarding the impact of creatine, the rise of HDDW’s “treatment now” program ten years ago, and the advent of both CREST-E and a companion study in presymptomatic individuals known as PRECREST led to much discussion about the supplement in the HD community.

Many people have taken or considered taking creatine in the hopes of avoiding or ameliorating symptoms.

I have taken creatine for about ten years, beginning with my participation in the HDDW program.

Just after receiving the news about CREST-E yesterday, I received an e-mail from an individual inquiring about where to purchase creatine and what amount to take. I responded that “it is now recommended that nobody take creatine.”

HDBuzz.net also reported on the end of CREST-E, calling the new evidence against creatine “compelling.”

Awaiting HD-specific remedies

In mid-August, the National Institute of Neurological Disorders and Stroke and the HSG stopped a clinical trial for coenzyme Q10, another widely taken supplement.

I outlined my approach to HD supplements and the pros and cons of the matter in a February article titled “To take, or not to take, unproven supplements in the fight against Huntington’s disease.” That article also reported on the hopes for PRECREST and CREST-E.

With the elimination of both coenzyme Q10 and creatine in rapid succession, the HD community is suddenly left without two potential treatments that supplied significant  hope.

However, supplements lack what researchers refer to as HD-specific approaches to treatments. They were not designed or marketed with HD in mind, whereas the new treatments currently under study will potentially attack the specific causes of Huntington’s.

Hope for effective treatments is on the rise as researchers and pharmaceutical firms gear up for new clinical trials such as the Isis Pharmaceuticals, Inc., gene-silencing approach announced for the first half of 2015.

“The important thing right now is to learn from ‘negative’ outcomes like this,” the HDBuzz article observed. “Studies like CREST-E have helped us, as a community, to get really good at designing, enrolling and running clinical trials, and understanding why particular treatments don’t work. Now we have the result of CREST-E, all that energy, enthusiasm and experience can be directed into testing other experimental treatments with a higher chance of success. One very solid benefit is that hundreds of volunteers are now freed up to sign up for other clinical trials enrolling now or in the near future.”

For the latest news on HD research and clinical trials, watch the video below for the update by Jody Corey-Bloom, M.D., Ph.D. (Note that the talk took place on October 27, before the announcement about creatine.)


The dire need for neurological treatments

I am now rethinking my approach to supplements. I have stopped taking coenzyme Q10.

I agree with the doctors’ recommendations to halt creatine. My breakfasts and dinners will no longer include a heaping teaspoon of fruit-flavored creatine dissolved in a glass of water.


Container with over-the-counter creatine (photo by Gene Veritas)


I will discard my remaining supply of creatine but keep the container as a piece of historical evidence in the quest for HD treatments.

It will also serve as a reminder of the dire need for truly effective approaches against a devastating disease that has reminded the world how the discovery of the first effective drug for any neurological disorder has continued to elude science.

Friday, August 15, 2014

Bidding farewell to CoQ10: a long-studied supplement proves ineffective in the fight against Huntington’s disease

One of the first and most-studied potential treatments for alleviating the symptoms of  Huntington’s disease has proved ineffective, leading researchers to halt a clinical trial of the substance.

Along with many others in the HD community, I have taken the readily available supplement coenzyme Q10 (CoQ10). As I wrote in a February article about the debate over unproven supplements, the lack of a treatment to slow HD’s devastation of the brain led me to take several of these substances in the hopes of staving off onset (click here to read more).

As reported August 13 by the HD science portal HDBuzz.net, the National Institute of Neurological Disorders and Stroke (NINDS) and the Huntington’s Study Group (HSG) stopped the CoQ10 clinical trial this week because of lack of significant results.

“It seems clear now that coenzyme Q10 does not work for HD,” the HDBuzz article stated. “Looking back, the body of evidence used to decide to test CoQ10 in human patients was fairly limited. In fact, recent efforts to repeat the observation that CoQ10 makes HD mice better have failed.”

According to HDBuzz, the trial known as 2Care, was the “largest ever therapeutic trial for Huntington’s disease.” It had enrolled 609 participants with early HD symptoms from 48 sites throughout North America and Australia. Half received a placebo, while the other half took 2,400 mg of CoQ per day – four times the amount that I have taken.


My supplements, including coenzyme Q10 at far left (photo by Gene Veritas)

A natural substance, CoQ10 is found in all of our cells and helps to turn food into chemical energy. Starting in the mid-1990s, scientists hypothesized that CoQ10 might help alleviate the serious energy deficits found in the brains of HD patients.

In another recent clinical trial, CoQ10 was also shown to have no benefit in stopping early Parkinson’s disease symptoms.

After consulting with several HD specialists, I have decided to stop taking CoQ10. Given the demonstrated lack of efficacy against HD, I see no reason to continue.

Also, although inexpensive over-the-counter varieties of CoQ10 exist, I have taken a medical-grade form that has cost me $1,000 per year. (Health plans do not cover supplements.) I can use that money to relieve strain on the family budget and/or spend it on services such as psychotherapy that help me cope with my situation as an HD gene carrier.

For now, I will continue to take other supplements as detailed in my February article: trehalose, creatine, omega-3 oil, and blueberry extract. However, I also plan to carefully rethink this strategy in consultation with my neurologist and HD specialists. (For a 2012 overview of key supplements and HD by Dr. LaVonne Goodman, please click here.)

A process of elimination

“While the results of this study are disappointing to all of us – particularly the people with HD who faithfully took the drug …  every day for as long as five years, and subjected themselves to blood draws and neurologic exams and questionnaires and surveys as part of their participation in the study – they are nonetheless very important,” Martha Nance, M.D., the director of the Huntington’s Disease Society of America (HDSA) Center of Excellence at Hennepin County Medical Center in Minneapolis wrote in an e-mail response to my request for comment. “Knowing that coenzyme Q10 DOESN’T work will spare the HD families of today and tomorrow the expense of the supplement, and the false hope that it created.”


Dr. Martha Nance: trial result ends "false hope" about CoQ10.

“Nobody said that finding a cure for HD would be easy, but I think that HD patients and families should be enormously proud of their efforts in this study – a commitment that can only help us with the future trials and challenges ahead,” Jody Corey-Bloom, M.D., Ph.D., the director of the HDSA Center of Excellence at the University of California, San Diego, wrote in an e-mail.

The process of elimination in scientific and clinical research is a slow, meticulous, but necessary part of the quest for treatments. Only one in ten clinical trials results in an effective drug. Understanding what doesn’t work expands scientists’ knowledge of the disease.

“We can now divert the resources that were going to be used for the 2CARE study to other studies with a better chance of working,” the HDBuzz article pointed out. “In fact, it’s likely that the next year or two will see the launch of several trials targeting specific mechanisms underlying HD, rather than ‘generally beneficial’ compounds like CoQ10.”

Added Dr. Nance: “We are actively pursuing many other avenues in HD research, and hope that many people will share the wonderful attitude of my patient (I will call her Susan), who said: ‘So, Dr. Nance, I'm sorry that this one is over, but now can I enroll in another HD research study?!’”

Closing out a complex relationship

For me, the end of the 2Care trial closes out nearly two decades of a complex relationship with CoQ10.

I first started taking an over-the-counter variety in early 1996, just weeks after learning of my mother’s diagnosis for HD. With a 50-50 chance of inheriting the gene for a devastating, incurable brain disorder that was inexorably destroying my mother’s personality and ability to think and walk, I grasped for whatever might provide the slimmest of hope.

In the mid-2000s, I started taking a higher grade of CoQ10 along with other above-mentioned supplements in a study under the Huntington’s Disease Drug Works program, which at the time emphasized a “treatment now” approach for a community desperate for solutions. After the study ended, I continued to take the substances and paid for them out of pocket.

CoQ became part of my daily ritual. I broke up the 600 mg chalky, yellow, sweetened CoQ10 tablet into four parts, which I took methodically at breakfast, lunch, and before and after dinner.

Although I knew there was no evidence about CoQ10’s efficacy, I believe it may have had a placebo effect. At 54, I have passed my mother’s age of onset. Now whatever placebo effect might have existed will disappear. In my particular use of CoQ10 and the other supplements, however, an actual placebo effect is scientifically unproven. In addition, scientists are getting closer to understanding the factors (such as a modifier gene) that trigger HD onset.

Throughout my journey with CoQ10, I always viewed it as peripheral at best. I believed that the best hopes lay with the potential remedies such as gene silencing aimed at the root causes of the disease.

Knowing the complexity of HD, I knew that a dietary supplement such as CoQ10 provided no more than a sliver of hope.

As I bid farewell to CoQ10 and the idea that it could delay onset, I’m once again forced to rethink how to survive in the gray zone between my genetic test result and the inevitable onset of an incurable disease. With science as a guide, I'm adjusting what is essentially an attempt at self-treatment.

Wednesday, November 30, 2011

The Holy Grail of Huntington's disease research: the gene-positive, drug trials, and treatments

Living in the gray zone between my genetic test for Huntington’s disease and the inevitable but indefinite onset of this devastating brain disorder, I frequently feel forgotten in the excited discussion about impending clinical trials to test potential treatments.

HD researchers want to include people like me in trials, but haven’t yet found a way to do so.

I am a victim in waiting, but without any of the noticeable, classic symptoms that would qualify me for participation in a clinical trial.

Because so much of the effort against HD is geared to helping the affected and the caregivers, I sometimes sense that we, the asymptomatic (or pre-manifest) gene-positive, have been relegated to second priority.

Emotional impact

I recognize that I am, for the time being, relatively fortunate, but the situation of perceived neglect, although unintentional, impacts me emotionally.

I wonder if symptomatic people feel jealous towards me – just as I have occasionally reacted with a furious inner jealousy when I learn that someone has tested negative. In other instances, I have briefly felt smug when I’m around or am thinking about people with symptoms.

In yet other instances, I feel compassion – and even profound guilt. I tell myself, “You have no right to worry! You’re not even sick! Your life hasn’t even been affected by the disease!”

Mostly, I just feel lucky to function normally and to have the opportunity to enjoy daily life.

But then I remember, “Yes, I have been affected by this disease. It took Mom’s life at only age 68, and it has robbed me and my family of so many dreams.”

I literally dreamt about my status last night as my mind worked on this article: a team of HD medical specialists put me through a series of exams to see whether symptoms had begun, and, as I awaited the results, I used a large red marker to edit this text.

Not coincidentally, it’s time to set up my annual checkup at the Huntington’s Disease Society of America’s Center of Excellence for Family Services and Research at the University of California, San Diego.

So far, those checkups have not turned up any of HD’s classic, outwardly noticeable symptoms.

But I am hyper-conscious of the fact that HD affects the brain ten or more years before those symptoms start. If an effective treatment isn’t found in the next few years, I will be doomed to follow in my mother’s footsteps.

Unable to reach the finish line?

The feelings of vulnerability and abandonment are magnified when I remember that no current or impending HD clinical trial includes participation of those of us who are pre-manifest.

In short, everything is currently focused on stopping HD already in progress. Nobody has yet developed a workable strategy for preventing the onset of HD.

Along with the scientists I have interviewed over the years, I am confident that a significant treatment or series of treatments will become available in the next decade or so to ameliorate the symptoms. Of course, I also hope for a “cure,” but scientists don’t use that term. They talk of controlling or managing the disease, because, of course, the defective HD gene cannot be removed from the body.

But I’m deeply worried that scientists will still take many more years beyond that to discover treatments for people like me, treatments that can stave off onset and/or minimize symptoms.

Ever since I tested positive in 1999, I have been racing against my own interior genetic clock to avoid symptoms and support the HD movement.

But the probability that my symptoms will start in the next few years leaves me with the sensation of the marathon runner who glimpses the finish line but ultimately cannot reach it.

Participation in studies

For now, pre-manifest people can participate in research studies. Whereas clinical trials aim specifically to test the safety, tolerability, and efficacy of a drug, studies seek to provide further information about a disease and/or strategies for treating it.

Studies can also include a test of safety and tolerability of a substance, as exemplified in the PREQUEL study, an investigation of coenzyme Q-10 exclusively in a pre-manifest group of 90 individuals. PREQUEL also aims to “assess the usefulness of certain markers of HD in the blood, which may help measure the rate of the disease progression or effects of medication.” Its coordinators aim to use it as precursor to a clinical trial of coenzyme Q-10, an antioxidant produced in the brain and that has led to the improvement of symptoms in HD mouse models.

Major studies involving pre-manifest people include PREDICT-HD, COHORT, and the forthcoming Enroll-HD, a new, worldwide HD database expected to start gathering information in early 2012. (Click here to read my previous article on Enroll-HD). Enroll-HD is sponsored by the CHDI Foundation, Inc., the so-called “cure Huntington’s disease initiative,” a multi-million-dollar effort backed by a group of anonymous donors.

Through the above-mentioned Center of Excellence, I have participated in a number of studies, including COHORT, MRI studies, research involving HD and the sense of smell, and an experiment with instruments designed to measure loss in mobility. (Click here and here to read more.) I have also given blood and, for many years, participated in cognitive batteries and a Dementia Rating Scale study. I also took part as the only pre-manifest individual in the Huntington’s Disease Drug Works program’s "treatment now" observational trial of supplements, a rare opportunity for someone in my situation.

A ‘long time’ to gene-positive trials

The federal Food and Drug Administration (FDA) will not permit pre-manifest people to participate in clinical trials until beneficial results have first been demonstrated in symptomatic patients. The FDA also requires that researchers come up with useful ways to measure benefits in the pre-manifest.

I became acutely aware of the challenges of designing a drug for the pre-manifest during a July 2009 interview with Dr. Frank Bennett, the senior vice president for research at Isis Pharmaceuticals, Inc., in Carlsbad, CA. Along with CHDI, Isis is planning a clinical trial of a revolutionary drug that, if successful, would attack HD at its genetic roots and slow or perhaps even stop the progression of the disease in the brain.

Dr. Bennett told me that although the clinical trial will focus only on symptomatic patients, he was “optimistic” that a way could be found to help the pre-manifest, too.

Exhilarated by the promise of a potential “cure,” I wrote several enthusiastic articles about Isis.

But privately I also felt somewhat desperate, because, as Dr. Bennett explained, finding a solution for the pre-manifest would take a “long time.”

“Identifying when to start treating those patients is going to be a little tricky, as you might imagine, because you don’t want to do it too soon,” he said. By the same token, Dr. Bennett added, waiting too long would miss the opportunity to protect brain cells, which, once damaged, could not recover. “This is not a short-term fix but it’s something that’s going to take a large number of years to figure out how to optimally treat these patients.”

Other path-breaking clinical trials face similar hurdles. Alnylam Pharmaceuticals, which is close to starting its own clinical trial for a similar attack on the disease’s genetic causes, plans to inject its drug directly into the heads of patients, but they must first undergo an operation so that a very fine needle can be inserted into their brains (click here to read more). Medically, scientifically, and ethically speaking, only symptomatic patients can undergo the many risks of such a trial.

As Dr. Bennett and others have noted, the FDA will display great caution with these new kinds of drugs as well as the highly invasive delivery systems. Isis and Alnylam are striving to minimize levels of risk and invasiveness.

Seeking the Holy Grail

HD researchers face a major challenge in finding a treatment for the pre-manifest. It’s really the Holy Grail not only for HD, but also for other neurological diseases such as Alzheimer’s in which brain damage occurs many years before symptoms appear. Ideally, researchers want to design medications that will completely prevent these diseases.

In a recent e-mail to me, CHDI President Robi Blumenstein elaborated on this point with an analogy.

“The purpose of a cholesterol-lowering drug is to prevent heart disease, not lower cholesterol for its own sake,” he explained. “Cholesterol-lowering drugs were tested on people at risk for heart disease. By analogy, we would like to test HD drugs on gene-positive people (like you) at risk of developing symptoms of HD to see if the intervention prevents the appearance of symptoms (that is, slows or arrests the progression of the disease).”

So, as researchers ramp up to clinical trials, this challenge is gaining greater attention. At the World Congress on Huntington’s Disease in Melbourne, Australia, in early September, several scientists revealed their research into areas directly related to this challenge, including a study of brain changes in the pre-manifest, the development of measurements from MRI brain scans to predict and track symptoms, and a report on how functional MRI scans can detect brain activity changes before brain shrinkage occurs. (For details click here.)

In his remarks at the World Congress, Blumenstein pointed out that researchers need both gene-positive and affected individuals to participate in research studies now in order to prepare adequate measurement tools for clinical trials.

“It would be a shame if we have potential drugs to test but lack the tools to conduct the tests to see if they are having the desired effect,” Blumenstein wrote to me.

“What the FDA will accept for regulatory purposes (i.e., to approve a drug) and whether we can satisfy ourselves that we are on the right track scientifically to modify the disease are two different questions,” he added. “We will need people like you to participate in studies and, yes, trials to establish the latter. When we are successful with that the former may require some education and lobbying of the regulators to convince them that new approaches to approving drugs for genetic diseases are appropriate.”

Waiting in the wings

For the beleaguered Huntington’s disease community, clinical trials of potential treatments provide a ray of hope.

Looking back to my mother’s diagnosis in 1995, I recognize that researchers have made stunning progress. But big hurdles remain, especially in developing preventive treatments for the pre-manifest.

I share the researchers’ optimism, but I temper it with a sober assessment of the complexity of the challenges.

For me, time is ever more precious.

Once again, it’s crystal clear that researchers ultimately rely on the participation of HD-affected families. Everybody can play a part – the untested at risk and the pre-manifest in research studies, and the affected in clinical trials.

The affected will bravely pioneer treatments by initiating the trials.

For the time being, however, gene-positive individuals like me must wait in the wings.

But we can assist immensely by supporting the affected, advocating for the cause, and, perhaps most importantly, taking part in the appropriate studies and experiments.

Together we dream of the day when we can all declare: “I’m HD-free!”

Today, being gene-positive for Huntington’s disease threatens the well-being of me and my family. But if the science continues to accelerate, it will provide hope that carrying the HD gene will become little more than an inconvenience.

Monday, February 21, 2011

‘Drug hunters’ bring hope to Huntington’s families

Scientists and pharmaceutical companies are making steady progress in the search for treatments for Huntington’s disease, increasing the hope that this generation of HD-affected families will finally get long-awaited relief from its devastating, ultimately deadly symptoms.

This was the message of the Sixth Annual HD Therapeutics Conference, sponsored by the CHDI Foundation, Inc., from February 7-10, 2011, at the Parker Palm Springs hotel in Palm Springs, California.

After delivering the keynote address to about 250 prominent scientists, physicians, pharmaceutical representatives, and supporters of the HD cause on the evening of February 7, I spent the next three days observing scientists speak on the latest advances in HD research and their plans for finding treatments.

This was a conference of “drug hunters,” the people in the trenches of university, corporate, government, and foundation labs who are working as quickly as possible to develop a myriad of ways to stop HD.

Informally known as the “cure Huntington’s disease initiative,” CHDI invited researchers to outline progress in four main areas, which I describe below after the following overview interview with Robert Pacifici, Ph.D., CHDI’s chief scientific officer.

Overview video and summaries

Click “play” on the video below to see my interview with Dr. Pacifici. In addition to outlining the main points of the conference, Dr. Pacifici urged the HD community to participate in trials that will assist scientists in their quest for treatments.

You can also read a daily summary of the conference at the excellent new science website http://www.hdbuzz.net/.




Gene Veritas interviews CHDI chief researcher Robert Pacifici from Gene Veritas on Vimeo.


Area 1: Decreasing huntingtin

The first and most promising area involves the attempt to attack HD at its genetic roots. This approach is called “lowering huntingtin,” the protein produced in our cells by the huntingtin gene. HD people have a mutated gene, and that mutation produces a faulty huntingtin protein, which compromises the health of brain cells.

As a result, they have two kinds of this protein. There is the “good,” or normal, huntingtin, which is produced by the gene inherited from the non-HD parent. And there is “bad,” or abnormal or defective huntingtin, which is produced by the gene from the parent with HD.

“In my six years at CHDI, we’ve seen (potential drug) targets come and go,” said Douglas Macdonald, Ph.D., CHDI’s director of drug discovery. “Only one has continued: huntingtin.”

Above, Dr. Macdonald addresses the conference. Below, a slide from his presentation pointing out the need to lower huntingtin before symptoms begin (photos by Gene Veritas).


CHDI’s current budget stands at approximately $100 million, a substantial sum compared to the amounts available just a decade ago in the world of HD research. CHDI intends to spend about half of the drug development portion of its budget in the area of huntingtin lowering. This approach appears to come closest to the idea of a “cure,” although most scientists believe that HD will be merely controlled like diabetes or high cholesterol, and then only with a cocktail of drugs.

On this front CHDI has partnered with a number of firms and labs: Isis Pharmaceuticals, Inc. (click here to read more); Alnylam Pharmaceuticals; Evotec; Dr. Neil Aronin of the University of Massachusetts School of Medicine; Dr. Paul Patterson of the California Institute of Technology; Dr. Edvard Smith of the Karolinska Institutet in Stockholm, Sweden; and Dr. Robert M. Friedlander of the University of Pittsburgh School of Medicine. Novartis, one of the world’s largest pharmaceutical companies, is also engaged in this area of research.

Both Isis and Alnylam are very close to applying for permission from the Food and Drug Administration to begin human clinical trials with their potential drugs.

Challenges

While potentially very effective for those with HD, lowering huntingtin also poses several huge challenges for scientists, Dr. Macdonald pointed out.

What should be targeted, good or bad huntingtin or both? How much should the protein be lowered? What part of the brain should be treated? And at what stage of the disease should a drug be given to a patient or non-symptomatic, gene-positive individual such as myself?

After all, the huntingtin protein is needed for the development of the cell. Even defective huntingtin does some good, Dr. Macdonald explained.

Unfortunately, so far the potential drugs for lowering huntingtin do not distinguish between the good and the bad, so reducing the bad decreases the good by the same percentage. (I’ll be writing soon on how Isis is attempting to find a way to keep the good while lowering the bad.)

In an interview, world-renowned HD specialist Dr. Michael Hayden, of the University of British Columbia, told me that beyond decreasing the defective huntingtin, another solution would be to increase the supply of the good.

Huntingtin’s job

For a long time, scientists had no idea about the function of huntingtin. In the last few years, however, they have made a number of discoveries.

Huntingtin is like the spider at the middle of a web of cellular functions, explained Scott Zeitlin, Ph.D., of the University of Virginia School of Medicine. If you reduce its capabilities, you reduce the strands in the web, in other words, the things the cell can do. And if you remove it, you sever the strands, that is, you completely turn off important processes.

Dr. Scott Zeitlin explains the functions of the huntingtin protein (photo by Gene Veritas).

In his presentation, Dr. Zeitlin identified six major functions for huntingtin, including the transport of materials inside the cell, the decoding of genes, and regulating metabolism. On the whole, huntingtin helps keep the cell stable (protein homeostasis).

It also helps keep the brain as a whole stable.

Dr. Zeitlin also pointed out that huntingtin is important in the development of an embryo. Too little huntingtin in a mouse embryo, for example, causes the animal to be born deformed.

Other views on lowering huntingtin

Providing the example of protein regulation in another disease, Dr. Karen Chen of the Spinal Muscular Atrophy (SMA) Foundation demonstrated how an Isis compound has improved the health of mice afflicted with SMA. Adjusting huntingtin could work similarly in HD, she suggested.

In his presentation, Dr. Andreas Weiss of the Novartis Institute for Biomedical Research discussed the methods and technologies used to track the presence of normal and abnormal huntingtin in cells and brains. Data from these observations will help in the design and dosing of treatments – including, once again, the question of how much to lower huntingtin.

(For an informed outlook on lowering huntingtin and controlling HD, watch my interview with Dr. Hayden in the video below. Dr. Hayden’s lab collaborates with Isis on attempts to lower huntingtin. In this interview Dr. Hayden also recounts his journey from working as a young doctor in South Africa to conducting research in North America, and he discusses the increased number of HD patients and the deep discrimination faced by HD-affected families everywhere. For additional background on Dr. Hayden, read this article.)



Gene Veritas interviews Huntington's disease expert Michael Hayden from Gene Veritas on Vimeo.


Area 2: saving brain cells

The second main area for researchers involves the problem of dysfunctional brain cells and how to save them early enough to prevent the disease from advancing.

This portion of the conference focused on such key problems as synaptic dysfunction, the misfiring the synapses, where the signals between brain cells are carried. The deficit in brain cell activity was also examined. Researchers also addressed the problem of “excitatory cell death”, in which dying cells release chemicals that, in turn, overstimulate and cause damage to other cells.

Dr. Michael Orth of the University of Ulm, Germany, discussed transcranial magnetic stimulation (sending of weak electrical currents into the brain), a method he has used to measure brain activity in pre-symptomatic, gene-positive individuals like me. He observed abnormal activity in the motor cortex portion of the brain, the area responsible for movement. Chorea, or the shaking and trembling of the body, is one of the primary symptoms of HD.

Dr. Vahri Beaumont of CHDI outlined the organization’s programs for combating synaptic dysfunction, which is primarily the problem of miscommunication between neurons. She noted that such dysfunction can occur as early as two decades before a person has noticeable symptoms. A couple of compounds currently used in clinical trials for other diseases could be beneficial for HD patients, she suggested.

Along these lines, Dr. Pacifici noted that large pharmaceutical companies have shown great interest in this area of brain health and have developed many compounds. These compounds can be “repurposed” quickly and moved into HD trials in the near future.

Area 3: bioenergetics and HD

The third group of presentations focused on a well-known problem caused by HD: an individual’s extremely high usage of energy, which causes patients to lose weight. Scientists are examining the causes of this problem at the cellular level and seeking remedies.

This characteristic of HD has led patients and asymptomatic gene-positive individuals to take supplements such as coenzyme Q-10, creatine, and trehalose. These might increase cellular energy. These substances are under study by HD researchers.

This session of the conference included discussion of dysfunction in the mitochondria, the powerhouses of the cell, and possible drug targets.

Dr. Pacifici that scientists are seeking to understand the specific causes of the energy deficit in HD and match them up with possible drug molecules.

Area 4: fertilizers for the brain

The final portion of the conference focused on “neurotrophic factors” (growth factors), which help maintain brain cells and the brain’s functions.

In Dr. Pacifici’s words, neurotrophic factors are like “fertilizers” for the brain. With HD, there is a shortage of certain molecules – the fertilizer – which must be put back into the brain to make it grow new cells and stay healthy.

Dr. João Siffert of Ceregene described his company’s implementation of a Phase II human clinical trial for CERE-120, a drug that is intended to increase the growth factor neurturin in the brains of Parkinson’s disease patients. Ceregene is conducting pre-clinical research on CERE-120 for use in HD.

The protein BDNF

One of the most frequently mentioned growth factors in HD research is BDNF, a protein known as brain-derived neurotrophic factor. As stated by Dr. Jordi Alberch of the University of Barcelona, BDNF is a potent protector of neurons in the striatum, one of the areas of the brain most affected in HD. The level of BDNF decreases in HD patients.

In his presentation on brain receptors that link up with BDNF, Dr. Moses Chao of the New York University School of Medicine noted that the lack of the substance is a cause of the neuropsychiatric symptoms of HD (such as depression).


Dr. Moses Chao speaks on BDNF (photo by Gene Veritas).

BDNF, he observed, contributes to a number of important activities in the brain, including the development of the cytoskeleton (the skeleton of the cell) and the ability of the synapses to adjust their strength. BDNF also helps cells survive.

As Dr. Chao pointed out, scientists first thought it might be possible to inject BDNF directly into the brain to help patients. However, in their experiments they encountered difficulties in delivering the BDNF, and it proved to be very “sticky,” meaning that it did not move easily in the brain. There were also negative side effects.

More recently, Dr. Chao explained, scientists have sought ways to bypass these problems. That research has focused on the BDNF receptors, molecules in the brain that link to BDNF so that it can carry out its tasks. Scientists are also examining substances that can bind to the receptors and act as a substitute for BDNF.

Evidence has also shown for quite some time that certain chronic antidepressants increase BDNF levels.

Scientists have long known that exercise stimulates the production of BDNF. Therefore, Dr. Allan Tobin of CHDI has conducted a workshop to investigate the use of molecules that could mimic the effect of exercise on the brain and therefore increase BDNF levels.

In his presentation, Dr. Alex Kiselyov of CHDI reviewed several “paths” that might be followed in solving the BDNF deficit problem.

Visiting the poster session

As with most scientific conferences, the CHDI event included an area where scientists could present posters summarizing their research.

The collection of posters was like an ultra-advanced science fair. Authors gave short oral presentations to other scientists circulating through the area, and a panel of three judges chose the three top posters. After hearing formal presentations, the conference participants selected a winner.

(In the video below you can watch the scientists as they examine and discuss the posters.)



Huntington's disease drug hunters view posters at 2011 research conference from Gene Veritas on Vimeo.


This year’s winner was a poster by Dr. Ray Truant of McMaster University in Hamilton, Ontario, and his graduate students Nicholas Caron and Randy Atwal. It was titled “Measuring Flourescence Lifetime in Living Cells Reveals Huntingtin Exon1 Structure at Nanometer Resolution.” It was subtitled “N17 ‘Loop-back’ Model is Affected by Phosphorylation and Polyglutamine Expansion.”

As explained to me by Caron, the experiment involved the use of an extremely powerful laser microscope to examine the real time workings of live mouse cells. They observed actual protein-to-protein interactions.

The normal huntingtin protein has a kind of hinge, but the abnormal protein becomes too long and too rigid and thus makes this hinge less flexible.

The team concluded that they can use this technique to screen for small molecules that can influence the disease process within the cells. The goal is to find ways to reduce toxicity within cells.

Their research builds on the 2009 discovery of a “molecular switch” that might be used to stop part of the disease process in Huntington’s.

Ph.D. student Nick Caron (above) with the winning poster, and Dr. Ray Truant (below) explaining the team's project to the conference participants (photos by Gene Veritas).


Another piece of the puzzle

The featured speaker of the conference was the eminent neuroscientist Dr. Solomon H. Snyder of the University of Johns Hopkins Medical School.

Dr. Snyder provided a look back at the last five decades of discoveries about the brain, its receptors, and the many important kinds of drugs resulting from this research.

In 2009, he and other scientists in his lab reported a key new finding about HD involving a protein called Rhes. Located only in the striatum, Rhes binds to the huntingtin protein. When it binds with abnormal huntingtin, it causes cell death.

As Dr. Synder stated, the limited presence of Rhes in the striatum could help explain why that area of the brain suffers more damage than others.

Researchers are now looking for ways to stop the harmful effects of Rhes. Dr. Snyder stated that a Rhes drug might be safe, because its use would be required only in the brain, not all over the body.

CHDI’s key role

In the final session of the conference, Dr. Pacifici and two lead CHDI researchers summarized CHDI’s work in developing completely new compounds that might be able to treat other problems that occur in HD-afflicted brains. Dr. Ignacio Muñoz-Sanjuan, the vice president for biology, and Dr. Celia Dominguez, the vice president for chemistry, detailed the efforts to prepare two of these compounds for testing in animals.

(Watch the video below for a part of Dr. Muñoz-Sanjuan’s talk and to get a view of the scientists at work in the main conference room.)



Drug hunters at work at 2011 Huntington's disease meeting from Gene Veritas on Vimeo.


The development of these and other CHDI compounds reveals how the organization has assumed an ever more important leadership role in the search for treatments and a cure. As a virtual biotech company, CHDI not only contracts with other firms and labs to carry out research and testing, but pioneers in new areas. CHDI is determined to explore as many remedies as possible.

At this conference CHDI’s importance was further reflected by the record number of attendees and posters. In fact, this year the organizers needed to add a couple of extra rows of seats to accommodate attendees.

“At any time, CHDI is working full-speed on about ten different drug development projects,” noted Dr. Jeff Carroll (click here to read more), an HD researcher and, like me, gene-positive for the disease. “For a sense of scale, that’s more programs than most large pharmaceutical companies have in all areas of brain research, including much more common diseases like Alzheimer’s or Parkinson’s disease. CHDI is changing the pace and scope of HD drug development.”

Reasons for optimism

Dr. Pacifici concluded that HD families can “have hope.”

“There are an incredible number of shots on goal,” he said. “We’re doing this as quickly and as rationally as possible, and I think that there’s really good reason to be optimistic that within the next period of time we’re going to start seeing the creation of new chemical entities, new drugs that were specifically designed with Huntington’s in mind.”

“I can see that we’re getting to the final stretch. It’s been a long marathon,” said Dr. Hayden. “And I’m optimistic. I’ve been in this field for 34 years. We did the first predictive test 25 years ago in Vancouver in 1986. So we’ve watched the whole development.

“So for me the opportunity to work with many of these companies, keep them focused on the issues, and help to provide the reagents and resources to get this done is just an incredible privilege and an exciting time.

“We know that for families listening to this, every day counts.”

Friday, December 24, 2010

The best Christmas gift of all

This week I received the best Christmas gift of all: a clean bill of health during my annual visit to the local Huntington’s disease clinic.

I tested positive for the HD gene in 1999, and my mother died of the disease in early 2006 at the age of 68. I don’t know exactly when her symptoms began, but, as I look back, it seems that classic early signs such as mood swings and depression began in her late 40s.

I turn 51 on December 31, and I’m getting closer to the point at which my mother started having chorea, or the trembling of the limbs, one of the major symptoms of Huntington’s.

In order to monitor my health and strategize on ways to avoid onset of the disease, each year I undergo an examination at the Huntington’s Disease Society of America’s Center of Excellence for Family Services and Research at the University of California, San Diego. On December 14, I went through an intensive, two-hour battery of cognitive testing at the center. This past Tuesday, December 21, I was examined by one of the center’s physicians.

He found no evidence of chorea, and he informed me that my 2010 cognitive results matched the 2009 tests.

So I remain stable!

Bonus time

I felt enormously relieved.

The visits are extremely stressful, because there are no treatments for the root causes of HD. Symptoms eventually appear in all gene-positive individuals.

Onset would mean that I would begin a steady decline towards death. My mother’s symptoms got steadily worse. During the 15 years (or more) of the disease, she lost the ability to walk, talk, think, and swallow. She was only a faint shadow of herself when she died in a nursing home.

So I realized once again that every extra moment of good health is a bonus.

A winning team

The doctor recommended that I maintain my routine.

Since 2004 I have taken the main supplements recommended by the Huntington’s Disease Drug Works (HDDW) program: trehalose, creatine, coenzyme Q-10, omega-3 fish oil pills, and blueberry concentrate pills. Although there is some evidence suggesting these substances could affect HD, at this point there’s no way to prove that they have actually helped me.

But, the doctor said, they might be helping me to remain stable.

HDDW used to cover the cost of the supplements but is no longer doing so. I will have to shell out two or three thousand dollars annually to pay for them. Because they’re not officially approved remedies, insurance won’t cover them.

Nevertheless, the doctor said the cost is justified.

I agree. There’s a saying I learned in following Brazilian soccer: you don’t mess with a winning team.

In my case, the team includes far more than the supplements: pills to avoid depression and anxiety, psychotherapy, exercise, dedication to my family, the nurturing of my faith and spirituality, and sharing my journey as an HD-positive person through this blog.

The need for hope

In writing this, I must admit that part of me feels enormously guilty.

So many others in the HD community already experience terrible symptoms. Young, at-risk people struggle with the news of their parents’ diagnoses and decisions about genetic testing, and newly tested individuals who are gene-positive suddenly fear a dark future.

Will my desire to celebrate a symptom-free Christmas and New Year’s Eve make others in the community feel even more frustrated with their helpless predicaments?

Probably not. People in our community are generally very understanding and sympathetic with a whole range of situations. But I feel so badly for others – and want even more badly for a cure to come soon.

We in the HD community we all need hope – especially at this time of year.

I may never know why in the year 2010 I did not have symptoms. In 2011 they very well could start.

But my lack of symptoms could very well serve as a piece of evidence in the mystery of HD and the search for treatments and a cure. That, after all, is a big reason why the results of my cognitive testing go to the researchers.

And I want to help others.

A gift of health and time

On the brighter side, my current state of stable health will permit me to continue the fight for greater awareness about Huntington’s disease and the quest to end it.

As I noted in my previous entry, on February 7, 2011, I will represent the HD community as I give the keynote speech before scores of scientists at the “Super Bowl” of Huntington’s research.

More than ever before, I’ll be putting myself in the public eye and calling fervently for a cure.

Thanks to this year’s best Christmas present of all, I can carry out that mission with a strong and clear voice.